Supreme Court tentatively schedules landmark Quebec secularism case for March | Unpublished
Hello!
Source Feed: The Globe and Mail
Author: David Ebner
Publication Date: November 10, 2025 - 17:13

Stay informed

Supreme Court tentatively schedules landmark Quebec secularism case for March

November 10, 2025

The Supreme Court of Canada has tentatively scheduled its landmark hearing on Quebec’s secularism law and potential limits on the Charter’s notwithstanding clause for March.

The court’s registry office on Monday advised lawyers involved in the case that the hearing has been set within the timeframe of March 16 to 27. The notice underlined the word tentatively and said the hearing date will be confirmed or adjusted as the court determines its schedule.



Unpublished Newswire

 
Alberta Premier Danielle Smith pointed to her advisers when asked to explain how an Edmonton businessman whose contracts with the province’s health agency are now under scrutiny ended up in a hotel suite with her top lieutenants on the night of the 2023 provincial election. A Globe and Mail investigation published over the weekend examined the links between medical supply company executive Sam Mraiche and Ms. Smith’s government. The Globe found Mr. Mraiche, whose company MHCare was awarded more than $600-million in contracts with Alberta Health Services, had more extensive connections to...
December 1, 2025 - 22:01 | Matthew Scace, Emma Graney | The Globe and Mail
For now, Cole says he walks the perimeter of his home every night, checking for any unwanted visitors and hoping nothing like this happens again.
December 1, 2025 - 21:55 | Victoria Femia | Global News - Canada
More cases of prostate cancer were diagnosed at Stage 4 in recent years compared with about a decade earlier, a development that experts behind a new study suggest could be linked with official recommendations discouraging the use of a hotly debated screening test.The prostate-specific antigen test is a simple blood test that can serve as an early warning signal of cancer in men with no symptoms. But the test also has risks: It can lead to overdiagnosis and overtreatment of slow-growing prostate tumours that might never have caused harm had they remained undiscovered. For that reason, a...
December 1, 2025 - 20:45 | Kelly Grant | The Globe and Mail